article thumbnail

SkinVive by Juvéderm: The New Dermal Filler Coming to the US

XTalks

. “This unique product is a result of our vast experience in hyaluronic acid science and complements our current collection of hyaluronic acid products, with the Juvéderm collection of fillers and SkinMedica topicals.” “One key way to improve skin quality is by enhancing hydration.

Filler 92
article thumbnail

EU probes low platelet safety issue with COVID-19 shots

pharmaphorum

After reviewing the safety reports received so far, the Pharmacovigilance Risk Assessment Committee (PRAC) decided to request an in-depth review of all available data, including case reports, clinical trials and the published literature, from the respective marketing authorisation holders for these vaccines. AZ vaccine safety update.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bone Void Filler Cerament G: The Combination Product by BONESUPPORT Gets Market Authorization from the FDA

XTalks

Ceramanet G, a bone void filler with the antibiotic gentamicin, fills bone voids and immediately begins bone healing with protection. Cerament G is a bone void filler treatment that can fill the gaps in the affected bones and simultaneously deliver the antibiotic gentamicin to reduce the risk of reinfection. mg/mL of cerament paste.

Filler 98
article thumbnail

Renuvion Dermal Handpiece by Apyx Medical Gets FDA Clearance for Wrinkle Reduction

XTalks

Common anti-aging procedures include Botox or dermal fillers, which can reduce the appearance of wrinkles, sagging and increase volume in the face where desired. XTALKS WEBINAR: Diversity and Inclusion in Clinical Trials — Practical Steps for Patient Recruitment Strategies.

article thumbnail

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

We remain confident that results from this trial will be positive given the outstanding results observed in our Phase II clinical trial.”. Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. SOUTH SAN FRANCISCO, Calif.

Trials 40